The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome

Although biologics have demonstrated to be effective in T2-high asthma patients, there is little experience with these drugs in asthma-COPD overlap (ACO). The aim of this study was to compare the effectiveness of biologics in these two conditions. We included 318 patients (24 ACO and 297 asthma) tre...

Descripción completa

Detalles Bibliográficos
Autores: De Llano, LP, Rivas, DD, Malanda, NM, Moral, VP, Blanco, JAG, Munoz-Esquerre, M, Garcia-Moguel, I, Campos, RMD, Martinez-Moragon, E, Mena, AH, Cosio, BG, Galo, AP, Serrano, CC
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p8544
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8544
https://ddd.uab.cat/record/277690
Access Level:acceso abierto
Palabra clave:asthma
asthma-COPD overlap
COPD
id ES_b7d57de1e9bd3eefb65f22ff7ec7b098
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p8544
network_acronym_str ES
network_name_str España
repository_id_str
spelling The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap SyndromeDe Llano, LPRivas, DDMalanda, NMMoral, VPBlanco, JAGMunoz-Esquerre, MGarcia-Moguel, ICampos, RMDMartinez-Moragon, EMena, AHCosio, BGGalo, APSerrano, CCasthmaasthma-COPD overlapCOPDAlthough biologics have demonstrated to be effective in T2-high asthma patients, there is little experience with these drugs in asthma-COPD overlap (ACO). The aim of this study was to compare the effectiveness of biologics in these two conditions. We included 318 patients (24 ACO and 297 asthma) treated with monoclonal antibodies and followed for at least 12 months Omalizumab was the most frequently employed biologic agent both in patients with ACO and asthma. Asthma control test (ACT) scores after at least 12 months of biologic therapy were not significantly different between groups. The percentage of patients with >= 1 exacerbation and >= 1 corticosteroid burst was significantly higher in ACO patients (70.8 vs 27.3 and 83.3% vs 37.5%, respectively), whereas the percentage of "controlled" patients (with no exacerbations, no need for corticosteroids and ACT >= 20) was significantly lower (16.7% vs 39.7%). In conclusion, this report suggests that patients with ACO treated with biologics reach worse outcomes than asthma patients.DOVE MEDICAL PRESS LTD2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8544https://ddd.uab.cat/record/277690Journal of Asthma and AllergyISSN: 11786965reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p85442026-06-14T12:41:47Z
dc.title.none.fl_str_mv The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome
title The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome
spellingShingle The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome
De Llano, LP
asthma
asthma-COPD overlap
COPD
title_short The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome
title_full The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome
title_fullStr The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome
title_full_unstemmed The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome
title_sort The Response to Biologics is Better in Patients with Severe Asthma Than in Patients with Asthma-COPD Overlap Syndrome
dc.creator.none.fl_str_mv De Llano, LP
Rivas, DD
Malanda, NM
Moral, VP
Blanco, JAG
Munoz-Esquerre, M
Garcia-Moguel, I
Campos, RMD
Martinez-Moragon, E
Mena, AH
Cosio, BG
Galo, AP
Serrano, CC
author De Llano, LP
author_facet De Llano, LP
Rivas, DD
Malanda, NM
Moral, VP
Blanco, JAG
Munoz-Esquerre, M
Garcia-Moguel, I
Campos, RMD
Martinez-Moragon, E
Mena, AH
Cosio, BG
Galo, AP
Serrano, CC
author_role author
author2 Rivas, DD
Malanda, NM
Moral, VP
Blanco, JAG
Munoz-Esquerre, M
Garcia-Moguel, I
Campos, RMD
Martinez-Moragon, E
Mena, AH
Cosio, BG
Galo, AP
Serrano, CC
author2_role author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv asthma
asthma-COPD overlap
COPD
topic asthma
asthma-COPD overlap
COPD
description Although biologics have demonstrated to be effective in T2-high asthma patients, there is little experience with these drugs in asthma-COPD overlap (ACO). The aim of this study was to compare the effectiveness of biologics in these two conditions. We included 318 patients (24 ACO and 297 asthma) treated with monoclonal antibodies and followed for at least 12 months Omalizumab was the most frequently employed biologic agent both in patients with ACO and asthma. Asthma control test (ACT) scores after at least 12 months of biologic therapy were not significantly different between groups. The percentage of patients with >= 1 exacerbation and >= 1 corticosteroid burst was significantly higher in ACO patients (70.8 vs 27.3 and 83.3% vs 37.5%, respectively), whereas the percentage of "controlled" patients (with no exacerbations, no need for corticosteroids and ACT >= 20) was significantly lower (16.7% vs 39.7%). In conclusion, this report suggests that patients with ACO treated with biologics reach worse outcomes than asthma patients.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8544
https://ddd.uab.cat/record/277690
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=8544
https://ddd.uab.cat/record/277690
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv DOVE MEDICAL PRESS LTD
publisher.none.fl_str_mv DOVE MEDICAL PRESS LTD
dc.source.none.fl_str_mv Journal of Asthma and Allergy
ISSN: 11786965
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869417561525846016
score 15.811543

Similares en LA Referencia